Revenue at September 30, 2016
Sales variance stabilized at -2.3% at constant exchange rates
Level of sales in line with expectations
Villepinte, October 24, 2016 - Guerbet (FR0000032526 GBT), a global specialist in contrast agents and solutions for medical imaging, is reporting revenue of €568.4 million at September 30, 2016, up 65.4% from 2015, continuing the momentum started in the first half of 2016. This growth figure includes a negative currency impact of €13.4 million mainly from the Brazilian real and the Argentine peso. At constant exchange rates, the Group posted sales of €581.9 million, a limited decrease of 2.3% from the pro forma sales at the end of September 2015 and still in line with the sales stabilization target of +/-3%. With revenue of €191.7 million for third quarter 2016, the strong sales momentum remains comparable with second quarter 2016 (€193.0 million).
Consolidated Grouprevenue (IFRS)
|In millions of euros||9 months 2016||
9 months 2015
|Change||Reported 2015||1st half 2016||
1st half 2015
|Sales in Europe||274.3||282.7||-2.9%||236.7||189.7||187.5||+1.2%|
|Sales in Other Markets||294.1||313.1||-6.1%||106.9||187.0||210.3||-11.1%|
* Integration of CMDS activities
At constant exchange rates, sales growth is in line with the revenue stabilization objective (+/-3%)
In Europe, consolidated revenue at September 30, 2016 totaled €274.3 million compared with €282.7 million in 2015 in its pro forma version, including a negative currency impact of €2.8 million. The decline in sales was mainly confined to Russia. The region's third-quarter revenue totaled €84.6 million compared with €95.1 million in 2015 (pro forma).
Outside Europe, the Group's sales fell to €294.1 million compared with €313.1 million in 2015 (pro forma), including a negative currency effect of €10.6 million. At constant exchange rates, there was a slight decrease of 2.7%, benefiting particularly from sales of Dotarem ® in the US. Third-quarter revenue in Other Markets increased to €107.1 million compared with €102.8 million in 2015 (pro forma).
Favorable momentum in MRI and IRT, growth expected in X-ray and ISS
At constant exchange rates, the activity breaks down as follows:
2016 outlook: confirmation of annual targets
The performance level for the first nine months of the year is within the window of +/-3% announced as the full-year target, allowing the Group to confirm this goal.
2016 revenue: February 15, 2017, after trading
Guerbet is a pioneer in the contrast agent field, with 90 years' experience, and is the only pharmaceutical group dedicated to medical imaging worldwide. It offers a comprehensive range of X-Ray, Magnetic Resonance Imaging (MRI) and Interventional Radiology and Theranostics (IRT) products, along with a range of injectors and related medical devices to improve the diagnosis and treatment of patients. To discover new products and ensure future growth, Guerbet invests heavily in R&D, spending around 9% of its sales each year. Guerbet (GBT) is listed on Euronext Paris (Segment B - Mid Caps) and generated €789 million in pro forma revenue in 2015.
For more information about Guerbet, please visit www.guerbet.com
Jean-François Le Martret
Chief Financial Officer
(+33)(0)1 45 91 50 00
(+33)(0)1 56 88 11 25
(+33)(0)1 56 88 11 19
Last updated on: 25/10/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.